Med. praxi. 2014;11(6):249-253

Vascular disease in menopausal women

doc.MUDr.Michal Vrablík, Ph.D.
3. interní klinika 1. LF UK a VFN, Praha

Epidemiological data clearly show that overall cardiovascular mortality in women exceeds that in the male population. It is after menopause

that the woman's risk profile changes rapidly and, due to waning oestrogen production, there occur a number of adverse changes in humoral,

cardiovascular, and metabolic regulations, resulting in a steep increase in the overall cardiovascular risk in women. Even long-term vascular

risk in postmenopausal women can be reduced by determining the cardiovascular risk as well as actively searching for and intervening with

the major risk factors (dyslipidaemia, arterial hypertension, impaired glucose homeostasis, and smoking). In addition to lifestyle measures and

active treatment of tobacco addiction in smokers, the cornerstones of management strategies include statin intervention for dyslipidaemia,

regulating arterial hypertension by reducing the activity of the renin-angiotensin-aldosterone system, and affecting insulin resistance with

metformin in prediabetes/type 2 diabetes. Early detection and treatment of risk factors can improve the outcomes of cardiovascular disease

prevention (not only) in the population of postmenopausal women and reduce the sustained high residual cardiovascular risk in the population.

Keywords: menopause, risk factors, cardiovascular events, dyslipidaemia, hypertension, diabetes mellitus, hormonal replacement therapy

Published: December 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Vascular disease in menopausal women. Med. praxi. 2014;11(6):249-253.
Download citation

References

  1. Executive Writing Committee, Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011; 57:1404-23. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011; 124(19): 2145-2154. Go to original source... Go to PubMed...
  2. Lloyd-jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113(6): 791-798. Go to original source... Go to PubMed...
  3. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005; 111(4): 499-510. Go to original source... Go to PubMed...
  4. Bush TL. Evidence for primary and secondary prevention of coronary artery disease inwomen taking oestrogen replacement therapy. Eur Heart J. 1996; 17(Suppl D): 9-14. Go to original source... Go to PubMed...
  5. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991; 325(17): 1196-204. Go to original source... Go to PubMed...
  6. Soma MR, Osnago-gadda I, Paoletti R, et al. The lowering of lipoprotein [a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993; 153(12): 1462-1468. Go to original source...
  7. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. BiochemBiophys Res Commun. 1995; 214(3): 847-855. Go to original source... Go to PubMed...
  8. Ahmed MA, Hassanein KM. Effects of estrogen on hyperglycemia and liver dysfunction in diabetic male rats. Int J PhysiolPathophysiolPharmacol. 2012; 4(3): 156-166.
  9. Fait T, Vrablík M, Žižka Z, Koštířová M. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. Gynecol Obstet Invest. 2008; 65(1): 47-51. Go to original source... Go to PubMed...
  10. Fait T, Vokrouhlická J, Vrablík M, Jeníček J. Současné postavení hormonální substituční terapie. Časopis lékařů českých 2004; (7): 447-452.
  11. Definice metabolického syndromu podle Českého institutu metabolického syndromu, o.ps. Dostupná z: http://www.cims-ops.cz/cz/uvod. Cit. 24. 1. 2010.
  12. Qiao Q; DECODE Study Group.Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia. 2006; 49(12): 2837-2846. Go to original source... Go to PubMed...
  13. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011; 378(9799): 1297-1305. Go to original source... Go to PubMed...
  14. Yusuf S, Hawken S, Ounpuu S; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937-952. Go to original source... Go to PubMed...
  15. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012); The Fifth Joint Task Force of the ESC and other Societies on Cardiovascular Disese Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts): Eur Heart 2012 doi.10.1093/eurheartj/ehs092.
  16. Catapano AL, Reiner Z, Backer GD, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Aterosclerosis Society (EAS). Aterosclerosis 2011; 217: 3-46. Go to original source... Go to PubMed...
  17. Vrablík M. Reziduální riziko kardiovaskulárních příhod. Medicína po promoci 2009, 10(3): 60-64.
  18. Filipovský J, Widimský J Jr., Ceral J, Cífková R, Horký K, Linhart A, Monhart V, Rosolová H, Seidlerová J, Souček M, Špinar J, Vítovec J, Widimský J. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785-801. Go to PubMed...
  19. Vrablík M. Léčba diabetické dyslipidemie. Diabetology news 2014; 5: 4-11.
  20. Grady D, Herrington D, Bittner V. Heart and estrogen/progestin replacement study follow-up (HERS II). Cardiovascular disease outcomes during 6-8 years of hormone therapy. JAMA 2002; 288: 49-57. Go to original source... Go to PubMed...
  21. Writing Group for Women´s Health Initiative Investigartors. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA 2002; 288(3): 321-33. Go to original source... Go to PubMed...
  22. Rossouw JER, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477. Go to original source... Go to PubMed...
  23. Salpeter, SR., Walsh, JME., Greyber, E. et al.: Mortality associated with HRT in younger and older women. J Gen Intern Med 2004; 19: 791-804. Go to original source... Go to PubMed...
  24. Manson JE, Allison MA, Russouw JE, et al. Estrogen therapy and coronary-artefy calcification. NEJM 2007; 356: 2591-2602. Go to original source... Go to PubMed...
  25. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, K?ber L, Jensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.